The clinical relevance of the METTL1-TXNDC12-c-Myc axis was substantiated in HNSCC specimens, underlining the potential of targeting this pathway as a therapeutic strategy in HNSCC. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.